{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T00:48:34Z","timestamp":1789951714415,"version":"4.0.1"},"reference-count":62,"publisher":"Impact Journals, LLC","issue":"17","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2017,4,25]]},"DOI":"10.18632\/oncotarget.16304","type":"journal-article","created":{"date-parts":[[2017,3,17]],"date-time":"2017-03-17T07:53:34Z","timestamp":1489737214000},"page":"29187-29201","source":"Crossref","is-referenced-by-count":32,"title":["Combined inhibition of GLI and FLT3 signaling leads to effective anti-leukemic effects in human acute myeloid leukemia"],"prefix":"10.18632","volume":"8","author":[{"given":"Emily-Marie","family":"Latuske","sequence":"first","affiliation":[{"name":"Department of Oncology, Hematology and Bone Marrow Transplantation with Section Pneumology, Hubertus Wald University Cancer Center, University Medical Center Hamburg-Eppendorf, Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hauke","family":"Stamm","sequence":"additional","affiliation":[{"name":"Department of Oncology, Hematology and Bone Marrow Transplantation with Section Pneumology, Hubertus Wald University Cancer Center, University Medical Center Hamburg-Eppendorf, Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianne","family":"Klokow","sequence":"additional","affiliation":[{"name":"Department of Oncology, Hematology and Bone Marrow Transplantation with Section Pneumology, Hubertus Wald University Cancer Center, University Medical Center Hamburg-Eppendorf, Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabi","family":"Vohwinkel","sequence":"additional","affiliation":[{"name":"Department of Oncology, Hematology and Bone Marrow Transplantation with Section Pneumology, Hubertus Wald University Cancer Center, University Medical Center Hamburg-Eppendorf, Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jana","family":"Muschhammer","sequence":"additional","affiliation":[{"name":"Department of Oncology, Hematology and Bone Marrow Transplantation with Section Pneumology, Hubertus Wald University Cancer Center, University Medical Center Hamburg-Eppendorf, Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carsten","family":"Bokemeyer","sequence":"additional","affiliation":[{"name":"Department of Oncology, Hematology and Bone Marrow Transplantation with Section Pneumology, Hubertus Wald University Cancer Center, University Medical Center Hamburg-Eppendorf, Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manfred","family":"J\u00fccker","sequence":"additional","affiliation":[{"name":"Institute of Biochemistry and Signal Transduction, University Medical Center Hamburg-Eppendorf, Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maxim","family":"Kebenko","sequence":"additional","affiliation":[{"name":"Department of Oncology, Hematology and Bone Marrow Transplantation with Section Pneumology, Hubertus Wald University Cancer Center, University Medical Center Hamburg-Eppendorf, Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter","family":"Fiedler","sequence":"additional","affiliation":[{"name":"Department of Oncology, Hematology and Bone Marrow Transplantation with Section Pneumology, Hubertus Wald University Cancer Center, University Medical Center Hamburg-Eppendorf, Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasmin","family":"Wellbrock","sequence":"additional","affiliation":[{"name":"Department of Oncology, Hematology and Bone Marrow Transplantation with Section Pneumology, Hubertus Wald University Cancer Center, University Medical Center Hamburg-Eppendorf, Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7892","published-online":{"date-parts":[[2017,3,16]]},"reference":[{"key":"1","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1101\/gad.938601","article-title":"Hedgehog signaling in animal development: paradigms and principles","volume":"15","author":"McMahon","year":"2001","journal-title":"Genes Dev"},{"key":"2","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1038\/nature03100","article-title":"Tissue repair and stem cell renewal in carcinogenesis","volume":"432","author":"Berman","year":"2004","journal-title":"Nature"},{"key":"3","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/35077219","article-title":"The Hedgehog and Wnt signalling pathways in cancer","volume":"411","author":"Beachy","year":"2001","journal-title":"Nature"},{"key":"4","first-page":"181","article-title":"Hedgehog beyond medulloblastoma and basal cell carcinoma","volume":"1805","author":"Toftg\u00e5rd","year":"2010","journal-title":"Biochim Biophys Acta"},{"key":"5","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1038\/nature07737","article-title":"Hedgehog signalling is essential for maintenance of cancer stem cells in myeloid leukaemia","volume":"458","author":"Beachy","year":"2009","journal-title":"Nature"},{"key":"6","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/1756-9966-30-8","article-title":"Activation of the Hedgehog pathway in chronic myelogeneous leukemia patients","volume":"30","author":"Meng","year":"2011","journal-title":"J Exp Clin Cancer Res"},{"key":"7","doi-asserted-by":"crossref","first-page":"4048","DOI":"10.1073\/pnas.0611682104","article-title":"Hedgehog signaling maintains a tumor stem cell compartment in multiple myeloma","volume":"104","author":"Matsui","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"key":"8","doi-asserted-by":"crossref","first-page":"2388","DOI":"10.1158\/1078-0432.CCR-14-1059","article-title":"Expression of Hedgehog pathway mediator GLI represents a negative prognostic marker in human acute myeloid leukemia and its inhibition exerts anti-leukemic effects","volume":"21","author":"Thol","year":"2015","journal-title":"Clin Cancer Res"},{"key":"9","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.canlet.2015.11.006","article-title":"Non-canonical GLI1\/2 activation by PI3K\/AKT signaling in renal cell carcinoma: A novel potential therapeutic target","volume":"370","author":"Wu","year":"2016","journal-title":"Cancer Lett"},{"key":"10","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.cellsig.2014.11.022","article-title":"ErbB2 signaling activates the Hedgehog pathway via PI3K-Akt in human esophageal adenocarcinoma: identification of novel targets for concerted therapy concepts","volume":"27","author":"Fiedler","year":"2015","journal-title":"Cell Signal"},{"key":"11","doi-asserted-by":"crossref","first-page":"6981","DOI":"10.1158\/0008-5472.CAN-07-0491","article-title":"Induction of sonic hedgehog mediators by transforming growth factor-beta: Smad3-dependent activation of Gli2 and Gli1 expressionand","volume":"67","author":"Mauviel","year":"2007","journal-title":"Cancer Res"},{"key":"12","doi-asserted-by":"crossref","unstructured":"Stone, Mandrekar, Sanford, Geyer, Bloomfield, Dohner, Thiede, Marcucci, Lo-Coco, Klisovic, Wei, Sierra, Sanz, et al. The Multi-Kinase Inhibitor Midostaurin (M) Prolongs Survival Compared with Placebo (P) in Combination with Daunorubicin (D)\/Cytarabine (C) Induction (ind), High-Dose C Consolidation (consol), and As Maintenance (maint) Therapy in Newly Diagnosed Acute Mye. 57th ASH Annu Meet Expo. 2015. Abstract 6.","DOI":"10.1182\/blood.V126.23.6.6"},{"key":"13","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1016\/S1470-2045(15)00362-9","article-title":"Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial","volume":"16","author":"Neubauer","year":"2015","journal-title":"Lancet Oncol"},{"key":"14","doi-asserted-by":"crossref","first-page":"3110","DOI":"10.1200\/JCO.2012.46.4990","article-title":"Sorafenib in combination with intensive chemotherapy in elderly patients with acute myeloid leukemia: results from a randomized, placebo-controlled trial","volume":"31","author":"Neubauer","year":"2013","journal-title":"J Clin Oncol"},{"key":"15","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1111\/bjh.13353","article-title":"A phase I\/II study of sunitinib and intensive chemotherapy in patients over 60 years of age with acute myeloid leukaemia and activating FLT3 mutations","volume":"169","author":"D\u00f6hner","year":"2015","journal-title":"Br J Haematol"},{"key":"16","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1756-8722-4-13","article-title":"Downstream molecular pathways of FLT3 in the pathogenesis of acute myeloid leukemia: biology and therapeutic implications","volume":"4","author":"Takahashi","year":"2011","journal-title":"J Hematol Oncol"},{"key":"17","doi-asserted-by":"crossref","first-page":"4505","DOI":"10.1073\/pnas.0504337103","article-title":"Phosphoinositide 3-kinase and Akt are essential for Sonic Hedgehog signaling","volume":"103","author":"Emerson","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"18","doi-asserted-by":"crossref","first-page":"2606","DOI":"10.1158\/1535-7163.MCT-06-0433","article-title":"Mutation analysis of 24 known cancer genes in the NCI-60 cell line set","volume":"5","author":"Clements","year":"2006","journal-title":"Mol Cancer Ther"},{"key":"19","doi-asserted-by":"crossref","first-page":"291ra96","DOI":"10.1126\/scitranslmed.aaa5731","article-title":"Integration of Hedgehog and mutant FLT3 signaling in myeloid leukemia","volume":"7","author":"Peacock","year":"2015","journal-title":"Sci Transl Med"},{"key":"20","doi-asserted-by":"publisher","first-page":"33004","DOI":"10.18632\/oncotarget.8844","article-title":"Gli-1\/PI3K\/AKT\/NF-kB pathway mediates resistance to radiation and is a target for reversion of responses in refractory acute myeloid leukemia cells","volume":"7","author":"Meng","year":"2016","journal-title":"Oncotarget"},{"key":"21","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.ccr.2011.12.028","article-title":"The crosstalk of mTOR\/S6K1 and Hedgehog pathways","volume":"21","author":"Huo","year":"2012","journal-title":"Cancer Cell"},{"key":"22","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1101\/gad.1753809","article-title":"GLI1 is regulated through Smoothened-independent mechanisms in neoplastic pancreatic ducts and mediates PDAC cell survival and transformation","volume":"23","author":"Hanahan","year":"2009","journal-title":"Genes Dev"},{"key":"23","doi-asserted-by":"crossref","first-page":"14048","DOI":"10.1074\/jbc.M611089200","article-title":"Oncogenic KRAS activates hedgehog signaling pathway in pancreatic cancer cells","volume":"282","author":"Cheng","year":"2007","journal-title":"J Biol Chem"},{"key":"24","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/j.exphem.2016.08.009","article-title":"Primary cilia are present on human blood and bone marrow cells and mediate Hedgehog signaling","volume":"44","author":"Merchant","year":"2016","journal-title":"Exp Hematol"},{"key":"25","doi-asserted-by":"crossref","first-page":"5895","DOI":"10.1073\/pnas.0700776104","article-title":"Melanomas require HEDGEHOG-GLI signaling regulated by interactions between GLI1 and the RAS-MEK\/AKT pathways","volume":"104","author":"Ruiz I Altaba","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"key":"26","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1182\/blood-2004-05-1846","article-title":"A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease","volume":"105","author":"Brega","year":"2005","journal-title":"Blood"},{"key":"27","doi-asserted-by":"crossref","first-page":"3669","DOI":"10.1182\/blood-2003-11-3775","article-title":"Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia","volume":"103","author":"Small","year":"2004","journal-title":"Blood"},{"key":"28","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1182\/blood-2004-03-0891","article-title":"Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412","volume":"105","author":"Clark","year":"2005","journal-title":"Blood"},{"key":"29","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1038\/leu.2012.105","article-title":"High activity of sorafenib in FLT3-ITD-positive acute myeloid leukemia synergizes with allo-immune effects to induce sustained responses","volume":"26","author":"M\u00fcller","year":"2012","journal-title":"Leukemia"},{"key":"30","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1038\/leu.2012.195","article-title":"FLT3 inhibition: a moving and evolving target in acute myeloid leukaemia","volume":"27","author":"Kwong","year":"2013","journal-title":"Leukemia"},{"key":"31","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1517\/14728222.2014.960843","article-title":"Targeting FLT3 to treat leukemia","volume":"19","author":"Levis","year":"2015","journal-title":"Expert Opin Ther Targets"},{"key":"32","doi-asserted-by":"crossref","first-page":"3294","DOI":"10.1182\/blood-2010-08-301796","article-title":"Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse","volume":"117","author":"Godley","year":"2011","journal-title":"Blood"},{"key":"33","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.clml.2011.06.007","article-title":"Patterns of molecular response to and relapse after combination of sorafenib, idarubicin, and cytarabine in patients with FLT3 mutant acute myeloid leukemia","volume":"11","author":"Ravandi","year":"2011","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"34","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1200\/JCO.2009.25.4888","article-title":"Phase I\/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia","volume":"28","author":"Byrd","year":"2010","journal-title":"J Clin Oncol"},{"key":"35","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1038\/leu.2012.115","article-title":"Phase IB study of the FLT3 kinase inhibitor midostaurin with chemotherapy in younger newly diagnosed adult patients with acute myeloid leukemia","volume":"26","author":"Giles","year":"2012","journal-title":"Leukemia"},{"key":"36","doi-asserted-by":"crossref","first-page":"2522","DOI":"10.1158\/1535-7163.MCT-06-0071","article-title":"The antitumor effects of sunitinib (formerly SU11248) against a variety of human hematologic malignancies: enhancement of growth inhibition via inhibition of mammalian target of rapamycin signaling","volume":"5","author":"Taguchi","year":"2006","journal-title":"Mol Cancer Ther"},{"key":"37","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/j.leukres.2007.09.017","article-title":"Blockade of MEK\/ERK signaling enhances sunitinib-induced growth inhibition and apoptosis of leukemia cells possessing activating mutations of the FLT3 gene","volume":"32","author":"Yokoyama","year":"2008","journal-title":"Leuk Res"},{"key":"38","first-page":"1425","article-title":"Targeting hedgehog signaling in cancer: research and clinical developments","volume":"6","author":"Gu","year":"2013","journal-title":"Onco Targets Ther"},{"key":"39","doi-asserted-by":"crossref","unstructured":"Jamieson, Cortes, Oehler, Baccarani, Kantarjian. Phase 1 Dose-Escalation Study of PF-04449913, An Oral Hedgehog (Hh) Inhibitor, in Patients with Select Hematologic Malignancies. 53rd ASH Annu Meet Expo. 2011. Abstract 424.","DOI":"10.1182\/blood.V118.21.424.424"},{"key":"40","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1001\/archdermatol.2012.2354","article-title":"Initial assessment of tumor regrowth after vismodegib in advanced Basal cell carcinoma","volume":"148","author":"Oro","year":"2012","journal-title":"Arch Dermatol"},{"key":"41","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/j.jaad.2014.08.001","article-title":"Acquired resistance to the Hedgehog pathway inhibitor vismodegib due to smoothened mutations in treatment of locally advanced basal cell carcinoma","volume":"71","author":"Mosterd","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"42","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1056\/NEJMoa0902903","article-title":"Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449","volume":"361","author":"de Sauvage","year":"2009","journal-title":"N Engl J Med"},{"key":"43","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1158\/0008-5472.CAN-10-2876","article-title":"Small molecule inhibition of GDC-0449 refractory smoothened mutants and downstream mechanisms of drug resistance","volume":"71","author":"Yauch","year":"2011","journal-title":"Cancer Res"},{"key":"44","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.molonc.2014.09.003","article-title":"Smoothened (SMO) receptor mutations dictate resistance to vismodegib in basal cell carcinoma","volume":"9","author":"Perrone","year":"2015","journal-title":"Mol Oncol"},{"key":"45","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.ccell.2015.02.001","article-title":"Genomic analysis of smoothened inhibitor resistance in basal cell carcinoma","volume":"27","author":"Sarin","year":"2015","journal-title":"Cancer Cell"},{"key":"46","first-page":"51ra70","article-title":"Interfering with resistance to smoothened antagonists by inhibition of the PI3K pathway in medulloblastoma","volume":"2","author":"Fordjour","year":"2010","journal-title":"Sci Transl Med"},{"key":"47","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1038\/nm0797-730","article-title":"Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell","volume":"3","author":"Dick","year":"1997","journal-title":"Nat Med"},{"key":"48","doi-asserted-by":"crossref","first-page":"966","DOI":"10.3324\/haematol.2011.054734","article-title":"Recent advances in acute myeloid leukemia stem cell biology","volume":"97","author":"Huntly","year":"2012","journal-title":"Haematologica"},{"key":"49","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/j.neo.2015.07.001","article-title":"Gli1-Mediated Regulation of Sox2 Facilitates Self-Renewal of Stem-Like Cells and Confers Resistance to EGFR Inhibitors in Non-Small Cell Lung Cancer","volume":"17","author":"Chellappan","year":"2015","journal-title":"Neoplasia"},{"key":"50","doi-asserted-by":"crossref","first-page":"e42","DOI":"10.1038\/oncsis.2013.5","article-title":"NVP-LDE-225 (Erismodegib) inhibits epithelial-mesenchymal transition and human prostate cancer stem cell growth in NOD\/SCID IL2R\u03b3 null mice by regulating Bmi-1 and microRNA-128","volume":"2","author":"Srivastava","year":"2013","journal-title":"Oncogenesis"},{"key":"51","doi-asserted-by":"publisher","first-page":"32039","DOI":"10.18632\/oncotarget.5055","article-title":"PI3K\/AKT\/mTOR and sonic hedgehog pathways cooperate together to inhibit human pancreatic cancer stem cell characteristics and tumor growth","volume":"6","author":"Srivastava","year":"2015","journal-title":"Oncotarget"},{"key":"52","doi-asserted-by":"crossref","first-page":"4697","DOI":"10.1038\/onc.2014.71","article-title":"SOX2 regulates self-renewal and tumorigenicity of human melanoma-initiating cells","volume":"33","author":"Stecca","year":"2014","journal-title":"Oncogene"},{"key":"53","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1186\/s12967-015-0453-9","article-title":"GLI2 inhibition abrogates human leukemia stem cell dormancy","volume":"13","author":"Moore","year":"2015","journal-title":"J Transl Med"},{"key":"54","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1111\/j.1349-7006.2009.01111.x","article-title":"Drug resistance is dramatically restored by hedgehog inhibitors in CD34+ leukemic cells","volume":"100","author":"Kato","year":"2009","journal-title":"Cancer Sci"},{"key":"55","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1159\/000443075","article-title":"Targeting GLI1 Suppresses Cell Growth and Enhances Chemosensitivity in CD34+ Enriched Acute Myeloid Leukemia Progenitor Cells","volume":"38","author":"Liu","year":"2016","journal-title":"Cell Physiol Biochem"},{"key":"56","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/1477-7819-11-25","article-title":"Expression of glioma-associated oncogene 2 (Gli 2) is correlated with poor prognosis in patients with hepatocellular carcinoma undergoing hepatectomy","volume":"11","author":"Xue","year":"2013","journal-title":"World J Surg Oncol"},{"key":"57","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1200\/JCO.2010.32.3295","article-title":"Glioma-associated oncogene family zinc finger 1 expression and metastasis in patients with head and neck squamous cell carcinoma treated with radiation therapy (RTOG 9003)","volume":"29","author":"Ang","year":"2011","journal-title":"J Clin Oncol"},{"key":"58","doi-asserted-by":"crossref","first-page":"116","DOI":"10.4132\/KoreanJPathol.2013.47.2.116","article-title":"Hedgehog related protein expression in breast cancer: gli-2 is associated with poor overall survival","volume":"47","author":"Kang","year":"2013","journal-title":"Korean J Pathol"},{"key":"59","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1007\/s12253-014-9774-x","article-title":"Activation of hedgehog signaling pathway in human non-small cell lung cancers","volume":"20","author":"Luo","year":"2014","journal-title":"Pathol Oncol Res"},{"key":"60","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1007\/s12032-011-9899-7","article-title":"Prognostic value of hedgehog signaling pathway in patients with colon cancer","volume":"29","author":"Zhang","year":"2012","journal-title":"Med Oncol"},{"key":"61","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/j.bcp.2010.04.016","article-title":"Small molecule modulation of HH-GLI signaling: current leads, trials and tribulations","volume":"80","author":"Ruiz i Altaba","year":"2010","journal-title":"Biochem Pharmacol"},{"key":"62","doi-asserted-by":"publisher","first-page":"13899","DOI":"10.18632\/oncotarget.4224","article-title":"Targeting the Hedgehog signaling pathway in cancer: beyond Smoothened","volume":"6","author":"Haustermans","year":"2015","journal-title":"Oncotarget"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.16304","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,10]],"date-time":"2020-05-10T18:58:44Z","timestamp":1589137124000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.16304"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3,16]]},"references-count":62,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2017,4,25]]}},"alternative-id":["16304","28418873"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.16304","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,3,16]]}}}